Form 4: Phibro Animal Health CEO-Controlled Entity Sells $1.3M Stock

Phibro Animal Health's President and CEO, Jack Bendheim, through BFI Co., LLC, sold 22,880 shares of Class A Common Stock for approximately $1.3 million via a Rule 10b5-1 plan.

Summary

• Jack Bendheim, President and CEO of Phibro Animal Health Corp (PAHC), and BFI Co., LLC, reported sales of Class A Common Stock.
• A total of 22,880 shares were sold by BFI Co., LLC between March 17, 2026, and March 19, 2026.
• These sales represent an indirect disposition for Jack Bendheim, who exercises voting and dispositive power over BFI Co., LLC.
• The sales were executed under a Rule 10b5-1 trading plan adopted by BFI Co., LLC on December 11, 2025.
• Transaction prices ranged from $51.19 to $53.88 per share, with weighted average prices for each block of shares.
• The total value of shares sold was approximately $1,298,782.77.
• Following these transactions, BFI Co., LLC holds 73,320 shares, and Jack Bendheim directly holds 16,840 shares.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a moderately negative signal. While the sales were pre-planned, significant insider selling by the CEO's controlled entity can erode investor confidence and suggest limited upside potential from management's perspective.

Negatives

• Significant insider selling by an entity controlled by the President and CEO, Jack Bendheim (BFI Co., LLC).
• The sales represent a reduction in indirect beneficial ownership by a key executive.
• Insider selling, even under a 10b5-1 plan, can be interpreted by the market as a lack of confidence in future stock performance.

Risks

• Potential negative market perception due to insider selling by an entity controlled by the CEO, which could put downward pressure on the stock price.
• Reduced alignment of interests between the CEO and common shareholders as his indirect holdings decrease.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that insider selling, even under a pre-arranged plan, can sometimes be viewed with caution by investors, particularly when it involves a high-ranking executive like the President and CEO. While 10b5-1 plans are designed to avoid accusations of trading on material non-public information, the sheer volume of sales can still influence market sentiment regarding the company's near-term prospects within the animal health sector.

Related Party Transactions

• Sales of Class A Common Stock by BFI Co., LLC, an entity over which Jack Bendheim, a director and officer, exercises voting and dispositive power, making it a related party transaction.

Stakeholder Impact

• Shareholders may interpret the insider selling by a CEO-controlled entity as a negative signal, potentially impacting investor confidence and the stock price.

Key Dates

Recommendation

While the insider selling by the CEO's controlled entity is a negative signal, the transactions were executed under a pre-arranged Rule 10b5-1 plan, which suggests the decision to sell was made in advance and not necessarily based on recent negative material non-public information. However, the volume of sales warrants caution, leading to a 'hold' recommendation rather than a 'buy' until further company-specific news or financial results provide a clearer picture of the company's fundamentals and future prospects. Investors should monitor future insider activity and company performance closely.

Keywords

Phibro Animal Health, PAHC, Jack Bendheim, Insider Selling, Form 4, SEC Filing, Stock Sale, Rule 10b5-1, CEO Stock Sale, Animal Health